Stockscreener 앱 받기
452.00
0.34%
-1.54
전일 마감가:
$453.54
열려 있는:
$453.45
하루 거래량:
751.38K
Relative Volume:
0.73
시가총액:
$59.25B
수익:
$2.46B
순이익/손실:
$-319.09M
주가수익비율:
-183.00
EPS:
-2.47
순현금흐름:
$-52.09M
1주 성능:
+1.23%
1개월 성능:
+7.90%
6개월 성능:
+81.36%
1년 성능:
+79.74%
1일 변동 폭
$444.65
$455.28
1주일 범위
$441.50
$458.30
52주 변동 폭
$205.87
$469.81
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Positive Long-Term HELIOS-B Results for AMVUTTRA - simplywall.st
Is Alnylam Pharmaceuticals Inc. a defensive stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - خودرو بانک
Is Alnylam Pharmaceuticals Inc. exposed to political riskJuly 2025 Decliners & Community Consensus Trade Signals - خودرو بانک
What are Alnylam Pharmaceuticals Inc.’s earnings expectationsEarnings Beat & Safe Entry Point Alerts - خودرو بانک
HC Wainwright Reiterates Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Intraday pattern recognizer results for Alnylam Pharmaceuticals Inc.2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - Newser
Visual analytics tools that track Alnylam Pharmaceuticals Inc. performance2025 Year in Review & Momentum Based Trading Ideas - Newser
Published on: 2025-09-06 00:28:49 - خودرو بانک
Can Alnylam Pharmaceuticals Inc. be the next market leader2025 Investor Takeaways & Reliable Volume Spike Trade Alerts - خودرو بانک
What to expect from Alnylam Pharmaceuticals Inc. in the next 30 days2025 Year in Review & Fast Exit and Entry Strategy Plans - Newser
Published on: 2025-09-05 14:03:59 - Newser
How to use a screener to detect Alnylam Pharmaceuticals Inc. breakoutsPortfolio Performance Summary & Free Fast Gain Swing Trade Alerts - Newser
Using RSI to spot recovery in Alnylam Pharmaceuticals Inc.Rate Cut & Safe Entry Point Identification - Newser
How high can Alnylam Pharmaceuticals Inc. stock goTrend Reversal & Reliable Trade Execution Plans - Newser
Multi asset correlation models including Alnylam Pharmaceuticals Inc.GDP Growth & AI Forecast Swing Trade Picks - Newser
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock? - Nasdaq
Best data tools to analyze Alnylam Pharmaceuticals Inc. stockWeekly Stock Report & Momentum Based Trading Ideas - Newser
RNA Therapeutics Market Size, Top Share | Industry Report, 2034 - Straits Research
Applying big data sentiment scoring on Alnylam Pharmaceuticals IncMarket Trend Report & High Return Trade Guides - Newser
Gene Therapy Market is expected to reach US$ 35.91 Billion by 2033 - openPR.com
Will Alnylam Pharmaceuticals Inc. outperform small cap indexes2025 Buyback Activity & Real-Time Buy Zone Alerts - خودرو بانک
Key resistance and support levels for Alnylam Pharmaceuticals Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - Newser
Regeneron posts late-stage trial win for myasthenia gravis drug developed with Alnylam - MSN
What does recent volatility data suggest for Alnylam Pharmaceuticals Inc.2025 Trade Ideas & Reliable Intraday Trade Alerts - Newser
Strategies to average down on Alnylam Pharmaceuticals Inc.Market Movers & Safe Entry Point Alerts - Newser
Quantitative breakdown of Alnylam Pharmaceuticals Inc. recent move2025 Technical Overview & Safe Entry Trade Signal Reports - Newser
What moving averages say about Alnylam Pharmaceuticals Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
Using Python tools to backtest Alnylam Pharmaceuticals Inc. strategiesJuly 2025 Summary & Daily Technical Forecast Reports - Newser
Market reaction to Alnylam Pharmaceuticals Inc.’s recent news2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - Newser
Alnylam at Citi’s Biopharma Conference: Launch Success and Future Plans - Investing.com
Sentiment analysis tools applied to Alnylam Pharmaceuticals Inc.July 2025 Opening Moves & Free Weekly Watchlist of Top Performers - Newser
The Strategic Value of Novartis' $5.2 Billion Argo Biopharma Licensing Deal in the RNAi Cardiovascular Therapeutics Space - AInvest
Technical analysis overview for Alnylam Pharmaceuticals Inc. stockJuly 2025 Outlook & Stepwise Trade Signal Implementation - Newser
How institutional ownership impacts Alnylam Pharmaceuticals Inc. stockJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Technical signs of recovery in Alnylam Pharmaceuticals Inc.July 2025 Volume & Fast Gaining Stock Reports - Newser
Will breakout in Alnylam Pharmaceuticals Inc. lead to full recovery2025 Earnings Surprises & Safe Entry Point Alerts - Newser
What MACD and RSI say about Alnylam Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - Newser
Using fundamentals and technicals on Alnylam Pharmaceuticals Inc.2025 Geopolitical Influence & Weekly Top Performers Watchlists - Newser
Published on: 2025-09-03 01:05:50 - Newser
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives - Seeking Alpha
Alnylam Pharmaceuticals Inc.’s volatility index tracking explained2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Chart overlay techniques for tracking Alnylam Pharmaceuticals Inc.Forecast Cut & High Accuracy Trade Alerts - Newser
What’s the analyst consensus on Alnylam Pharmaceuticals Inc.Stock Surge & Weekly Return Optimization Plans - خودرو بانک
Alnylam Shares Edge Up 0.11% on $480M Volume (Rank 222nd) as RNAi Pipeline Drives 70%+ Total Return - AInvest
How sentiment analysis helps forecast Alnylam Pharmaceuticals Inc.Quarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
Insider Sell: Tolga Tanguler Sells 3,474 Shares of Alnylam Pharm - GuruFocus
Is Alnylam Pharmaceuticals Inc. forming a breakout pattern2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.09%
자본화:
|
볼륨(24시간):